HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
NTLA
Intellia Therapeutics, Inc.
There isn't enough reported data to score NTLA yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
NTLA Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Under pressure | |
| Unavailable |
NTLA's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
NTLA PE Valuation
NTLA has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
NTLA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect NTLA's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
NTLA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.33 | +$0.94 |
| Q2 2026 | -$3.34 | +$1.35 |
| Q1 2026 | -$3.52 | +$1.71 |
| Q4 2025 | -$3.81 | +$1.44 |
| Q3 2025 | -$4.27 | +$1.17 |
| Q2 2025 | -$4.69 | +$0.79 |
| Q1 2025 | -$5.23 | +$0.13 |
| Q4 2024 | -$5.25 | +$0.16 |
NTLA has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over NTLA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over NTLA on profitability, with a higher operating margin.
NTLA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.2M | -48% |
| Q2 2026 | $7.7M | -46% |
| Q1 2026 | $15M | -9.5% |
| Q4 2025 | $23M | +79% |
| Q3 2025 | $13.8M | +51% |
| Q2 2025 | $14.2M | +105% |
| Q1 2025 | $16.6M | -43% |
| Q3 2024 | $9.1M | -24% |
NTLA's revenue has slid since its 2024 peak: $7M last quarter, down 48% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1708% | -899 points |
| Q2 2026 | -1472% | -700 points |
| Q1 2026 | -668% | +59 points |
| Q4 2025 | -429% | +631 points |
| Q3 2025 | -809% | +780 points |
| Q2 2025 | -772% | +1226 points |
| Q1 2025 | -727% | -333 points |
| Q4 2024 | -1060% | N/A |
NTLA's operating margin was −1708% last quarter, down 899 points from the same quarter a year ago, near the bottom of its range since 2019.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over NTLA on cash generation, producing positive trailing cash flow while its opponent burns cash.
NTLA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$86.3M | -$9.4M |
| Q2 2026 | -$84.9M | +$14.9M |
| Q1 2026 | -$117.4M | +$32.2M |
| Q4 2025 | -$69.4M | +$16.8M |
| Q3 2025 | -$76.9M | +$9.2M |
| Q2 2025 | -$99.9M | -$40.7M |
| Q1 2025 | -$149.7M | -$26.5M |
| Q4 2024 | -$86.2M | +$8.4M |
NTLA has burned cash in almost every quarter: −$358M over the past year, against −$413M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over NTLA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
NTLA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5% | +6.7M shares |
| 1 year | +27% | +30M shares |
| 3 years | +58% | +51.5M shares |
| 5 years | +106% | +72M shares |
| Available history | +184% | +90.8M shares |
NTLA has 140M diluted shares, up 27% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
NTLA Net Leverage
NTLA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
NTLA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.6 | Neutral |
| Stochastic | 30.2 | Neutral |
NTLA's weekly RSI is 43 (neutral) and its Stochastic is 30 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
NTLA PE vs Healthcare Sector
NTLA has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
NTLA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.8 | 10% below |
| 20 week MA | $12.2 | 14% below |
| 50 week MA | $12.5 | 16% below |
| 100 week MA | $11.9 | 11% below |
| 200 week MA | $20.8 | 49% below |
NTLA is in a downtrend: it's below all five of its weekly moving averages, and 49% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
NTLA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $15.4 | $62.1 | +304% |
| 2021 | $62.1 | $126.8 | +104% |
| 2022 | $126.8 | $35.0 | -72% |
| 2023 | $35.0 | $30.5 | -13% |
| 2024 | $30.5 | $12.0 | -61% |
| 2025 | $12.0 | $9.44 | -21% |
| 2026 YTD | $9.44 | $10.6 | +12% |
NTLA has the edge over HIMS on returns for 2026, with the stronger performance.